N-Gene ^Company

N-Gene is a developer of clinical-stage bio-pharmaceutical drugs designed to focus on the discovery, development, and commercialization of proprietary synthetic small molecules. The company's drugs use proprietary synthetic small molecule BGP-15 that has been found efficacious in various indications relating to adverse metabolic conditions, including type 2 diabetes mellitus by blocking JNK phosphorylation and has a new therapeutic effect via stress response modulation, enabling pharmaceutical companies to get a series of synthetic molecules to treat the insulin-resistance syndrome, improve cancer chemotherapy, and slow skin aging.